Alpha Tau Medical Ltd. (DRTS) Form 6-K — Jun 23, 2026
Alpha Tau Medical announced the successful treatment of the first recurrent glioblastoma patient outside of the United States using its Alpha DaRT technology at Hadassah University Medical Center in Israel. This procedure marks the first international clinical application of the Alpha DaRT brain-specific delivery system and was completed safely without unexpected complications. The patient was treated under the ALL clinical protocol, a broad-access study open to patients with solid tumors who have no standard treatment alternatives.
Key figures
- Patient Age Years
- 77
- Gbm Annual Global Cases
- approximately 160,000
- New USAcademic Centers
- 2
- Median Survival Recurrence Months
- 6 to 9
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.